Advertisement
Advertisement
LGND
Ligand Pharmaceuticals Inc.
308.30
USDSponsored
+4.77
+1.57%
Oct 26, 15:59 UTC -4
Closed
Pre-Market
308.19
-0.11
-0.03%
Ligand Pharmaceuticals Inc. (LGND) Earnings
LGND Earnings Reports
Positive Surprise Ratio
LGND beat 38 of 42 last estimates.
90%
Next Report
In 2 Days
Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$78.78M
/$2.42
Implied change from Q2 26 (Revenue/ EPS)
+23.68%
/+2.11%
Implied change from Q3 25 (Revenue/ EPS)
-9.34%
/-21.68%
Ligand Pharmaceuticals Inc. earnings per share and revenue
On Aug 06, 2026, LGND reported earnings of 2.37 USD per share (EPS) for Q2 26, beating the estimate of 1.86 USD, resulting in a 27.34% surprise. Revenue reached 63.69 million, compared to an expected 61.98 million, with a 2.76% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 2.42 USD, with revenue projected to reach 78.78 million USD, implying an increase of 2.11% EPS, and increase of 23.68% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
argenx SE - ADR
Report Date
Oct 22, 2026 For Q3 26
Estimate
$8.19
Actual
$7.80
Surprise
-4.84%
QIAGEN N.V.
Report Date
Oct 21, 2026 For Q3 26
Estimate
$0.63
Actual
$0.65
Surprise
+2.43%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Oct 26, 2026 For Q3 26
Estimate
-$0.39
Actual
-$0.35
Surprise
+11.79%
Tiziana Life Sciences Ltd. Common Shares
Report Date
Oct 16, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.10
Surprise
-22.55%
FAQ
What were Ligand Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ligand Pharmaceuticals Inc. reported EPS of $2.37, beating estimates by 27.34%, and revenue of $63.69M, 2.76% above expectations.
How did the market react to Ligand Pharmaceuticals Inc.'s Q2 2026 earnings?
The stock price moved down -0.8%, changed from $302.57 before the earnings release to $300.14 the day after.
When is Ligand Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Oct 29, 2026.
What are the forecasts for Ligand Pharmaceuticals Inc.'s next earnings report?
Based on --
analysts, Ligand Pharmaceuticals Inc. is expected to report EPS of $2.42 and revenue of $78.78M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.